Core Viewpoint - 英矽智能 has entered into an exclusive licensing and co-development agreement with Shenzhen Hengtai Biotechnology Co., Ltd. for the ISM8969 project, aimed at accelerating the global development of a new oral NLRP3 inhibitor for central nervous system diseases [1] Group 1: Agreement Details - The agreement grants Shenzhen Hengtai the rights to research, develop, register, produce, and commercialize ISM8969 globally, with both parties holding 50% global rights to the project [1] - 英矽智能 is entitled to receive up to $66 million (approximately HKD 514.8 million) in upfront and milestone payments, including an expected upfront payment of $10 million (approximately HKD 78 million) within 30 days of the agreement's effective date [1] Group 2: Company Background - Shenzhen Hengtai Biotechnology Co., Ltd. was incubated by Shenzhen Pengfu Biomedical Industry Private Equity Investment Fund Partnership and Fosun Pharma, focusing on innovative biotechnology in the field of autoimmune diseases [1] - Established in August 2025, the company aims to introduce and develop innovative pipelines with "best-in-class" potential globally, providing breakthrough treatment solutions through efficient R&D and commercialization capabilities [1]
英矽智能(03696.HK)与衡泰生物达成超过5亿港元的全球战略合作 共同开发新型血脑屏障穿透性NLRP3抑制剂